Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G MorrisBeaumont Hospital, Dublin, 9, IrelandTel +353...
Guardado en:
Autores principales: | Linehan AS, Fitzpatrick OM, Morris PG |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5755840965e249f389c2e1f705773c31 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021) -
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar I, et al.
Publicado: (2021) -
Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato Y, et al.
Publicado: (2021) -
Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Belal Firwana, et al.
Publicado: (2012) -
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)